Status:
COMPLETED
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
Lead Sponsor:
AstraZeneca
Conditions:
Metabolic Syndrome
Dyslipidemia
Eligibility:
MALE
45-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in rever...
Eligibility Criteria
Inclusion
- Signed informed consent
- males aged 45-65
- insulin resistance
- central obesity
- LDL-C \<6 mmol/L
- plasma triglycerides \>=1.7 and ≤5.5 mmol/L
- HDL-C ≤1.2 mmol/L.
Exclusion
- total cholesterol \>7mmol/L
- pre-existing cardiovascular disease, diabetes, proteinuria or renal failure
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00240266
Start Date
August 1 2003
End Date
December 1 2004
Last Update
November 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Melbourne, Victoria, Australia